Comparison of [¹¹¹In]pentetreotide-SPECT and [¹⁸F]FDOPA-PET in the localization of extra-adrenal paragangliomas : the case for a patient-tailored use of nuclear imaging modalities
© 2010 Blackwell Publishing Ltd..
AIMS AND METHODS: The aim of this prospective study was to compare the diagnostic value of [¹⁸F]FDOPA-PET and [¹¹¹In]pentetreotide-SPECT somatostatin receptor scintigraphy (SRS) in patients with nonmetastatic extra-adrenal paragangliomas (PGLs). Twenty-five consecutive unrelated patients who were known or suspected of having nonmetastatic extra-adrenal PGLs were prospectively evaluated with SRS and [¹⁸F]FDOPA-PET. ¹³¹I-MIBG and [¹⁸F]FDG-PET were added to the work-up in patients with a personal or familial history of PGL, predisposing mutations, abdominal PGLs, metanephrine hypersecretion and abdominal foci on SRS and/or [¹⁸F]FDOPA-PET.
RESULTS: SRS correctly detected 23/45 lesions of which 20 were head or neck lesions (H&N) and 3 were abdominal lesions. [¹⁸F]FDOPA-PET detected significantly more lesions than SRS (39/45, P < 0·001). Both SRS and ¹⁸F-DOPA-PET detected significantly more H&N than abdominal lesions (66·7% vs 20%, P = 0·003 and 96·7% vs 67%, P = 0·012, respectively). In two patients with the succinate dehydrogenase D (SDHD) mutation, [¹⁸F]FDOPA-PET missed five abdominal PGLs which were detected by the combination of SRS, [¹³¹I]MIBG and [¹⁸F]FDG-PET. A lesion-based analysis using a forward stepwise logistic regression model demonstrates that size ≤ 10 mm (P = 0·002) and abdominal lesions (P = 0·031) were independently associated with "[¹⁸F]FDOPA-PET diagnosis only". In turn, a previous history of surgery and/or the presence of germline mutation was associated with lower lesion size (P = 0·001).
CONCLUSIONS: The sensitivity of SRS for localizing parasympathetic PGLs is lower than originally reported, and [¹⁸F]FDOPA-PET is better than SRS for localizing small lesions. SRS should be replaced by [¹⁸F]FDOPA-PET as the first-line imaging procedure in H&N PGL, especially in patients at risk of multifocal disease (predisposing mutations and or previous history of surgery).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Clinical endocrinology - 74(2011), 1 vom: 15. Jan., Seite 21-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Charrier, N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
51110-01-1 |
|---|
| Anmerkungen: |
Date Completed 31.03.2011 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/j.1365-2265.2010.03893.x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM203271009 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM203271009 | ||
| 003 | DE-627 | ||
| 005 | 20231223225818.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/j.1365-2265.2010.03893.x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0678.xml |
| 035 | |a (DE-627)NLM203271009 | ||
| 035 | |a (NLM)21039729 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Charrier, N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of [¹¹¹In]pentetreotide-SPECT and [¹⁸F]FDOPA-PET in the localization of extra-adrenal paragangliomas |b the case for a patient-tailored use of nuclear imaging modalities |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2011 | ||
| 500 | |a Date Revised 19.11.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2010 Blackwell Publishing Ltd. | ||
| 520 | |a AIMS AND METHODS: The aim of this prospective study was to compare the diagnostic value of [¹⁸F]FDOPA-PET and [¹¹¹In]pentetreotide-SPECT somatostatin receptor scintigraphy (SRS) in patients with nonmetastatic extra-adrenal paragangliomas (PGLs). Twenty-five consecutive unrelated patients who were known or suspected of having nonmetastatic extra-adrenal PGLs were prospectively evaluated with SRS and [¹⁸F]FDOPA-PET. ¹³¹I-MIBG and [¹⁸F]FDG-PET were added to the work-up in patients with a personal or familial history of PGL, predisposing mutations, abdominal PGLs, metanephrine hypersecretion and abdominal foci on SRS and/or [¹⁸F]FDOPA-PET | ||
| 520 | |a RESULTS: SRS correctly detected 23/45 lesions of which 20 were head or neck lesions (H&N) and 3 were abdominal lesions. [¹⁸F]FDOPA-PET detected significantly more lesions than SRS (39/45, P < 0·001). Both SRS and ¹⁸F-DOPA-PET detected significantly more H&N than abdominal lesions (66·7% vs 20%, P = 0·003 and 96·7% vs 67%, P = 0·012, respectively). In two patients with the succinate dehydrogenase D (SDHD) mutation, [¹⁸F]FDOPA-PET missed five abdominal PGLs which were detected by the combination of SRS, [¹³¹I]MIBG and [¹⁸F]FDG-PET. A lesion-based analysis using a forward stepwise logistic regression model demonstrates that size ≤ 10 mm (P = 0·002) and abdominal lesions (P = 0·031) were independently associated with "[¹⁸F]FDOPA-PET diagnosis only". In turn, a previous history of surgery and/or the presence of germline mutation was associated with lower lesion size (P = 0·001) | ||
| 520 | |a CONCLUSIONS: The sensitivity of SRS for localizing parasympathetic PGLs is lower than originally reported, and [¹⁸F]FDOPA-PET is better than SRS for localizing small lesions. SRS should be replaced by [¹⁸F]FDOPA-PET as the first-line imaging procedure in H&N PGL, especially in patients at risk of multifocal disease (predisposing mutations and or previous history of surgery) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Receptors, Somatostatin |2 NLM | |
| 650 | 7 | |a Somatostatin |2 NLM | |
| 650 | 7 | |a 51110-01-1 |2 NLM | |
| 650 | 7 | |a pentetreotide |2 NLM | |
| 650 | 7 | |a G083B71P98 |2 NLM | |
| 700 | 1 | |a Deveze, A |e verfasserin |4 aut | |
| 700 | 1 | |a Fakhry, N |e verfasserin |4 aut | |
| 700 | 1 | |a Sebag, F |e verfasserin |4 aut | |
| 700 | 1 | |a Morange, I |e verfasserin |4 aut | |
| 700 | 1 | |a Gaborit, B |e verfasserin |4 aut | |
| 700 | 1 | |a Barlier, A |e verfasserin |4 aut | |
| 700 | 1 | |a Carmona, E |e verfasserin |4 aut | |
| 700 | 1 | |a De Micco, C |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, S |e verfasserin |4 aut | |
| 700 | 1 | |a Mancini, J |e verfasserin |4 aut | |
| 700 | 1 | |a Palazzo, F F |e verfasserin |4 aut | |
| 700 | 1 | |a Lavieille, J P |e verfasserin |4 aut | |
| 700 | 1 | |a Zanaret, M |e verfasserin |4 aut | |
| 700 | 1 | |a Henry, J F |e verfasserin |4 aut | |
| 700 | 1 | |a Mundler, O |e verfasserin |4 aut | |
| 700 | 1 | |a Taïeb, D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical endocrinology |d 1972 |g 74(2011), 1 vom: 15. Jan., Seite 21-9 |w (DE-627)NLM000089117 |x 1365-2265 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2011 |g number:1 |g day:15 |g month:01 |g pages:21-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1365-2265.2010.03893.x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2011 |e 1 |b 15 |c 01 |h 21-9 | ||